Lin­ing up against ri­vals, Am­gen and No­var­tis build a block­buster case for their CGRP mi­graine drug

Am­gen $AMGN and its part­ners at No­var­tis $NVS rolled out a fresh batch of solid­ly pos­i­tive da­ta from the lat­est Phase III study of their CGRP mi­graine drug erenum­ab, back­ing up their be­lief that they can break past a line­up of ri­vals and make a block­buster score fol­low­ing a near cer­tain ap­proval now on the hori­zon.

The drug, which they plan to sell as Aimovig, will like­ly be chal­lenged by a group of com­peti­tors from Eli Lil­ly $LLY, Te­va $TE­VA and Alder $AL­DR that have all demon­strat­ed broad­ly sig­nif­i­cant da­ta in cut­ting the num­ber of mi­graine days ex­pe­ri­enced by a chron­ic suf­fer­er. So they plan to hit the mar­ket with a bat­ter­ing ram of da­ta to help clear the way with providers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.